AIkido Pharma Shares Outstanding 2006-2021 | AIKI

AIkido Pharma shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
AIkido Pharma Annual Shares Outstanding
(Millions of Shares)
2020 28
2019 3
2018 2
2017 1
2016 1
2015 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2007 0
2006 0
2005 0
AIkido Pharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 90
2021-03-31 60
2020-12-31 28
2020-09-30 35
2020-06-30 33
2020-03-31 9
2019-12-31 3
2019-09-30 2
2019-06-30 2
2019-03-31 2
2018-12-31 2
2018-09-30 2
2018-06-30 2
2018-03-31 2
2017-12-31 1
2017-09-30 1
2017-06-30 1
2017-03-31 1
2016-12-31 1
2016-09-30 1
2016-06-30 1
2016-03-31 1
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31 0
2013-09-30 0
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30 0
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30 0
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.070B $0.000B
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71